DBV Technologies Shares Fall 4.21% Despite a 176% Gain Over One Year
On Tuesday, April 7, the stock of the biotech company specializing in food allergies saw a sharp decline in a generally downward Parisian market. With a price at €3.48, DBV Technologies has erased some of the gains accumulated in recent months, although its performance over one year remains significantly positive at over 176%.
DBV Technologies' stock drops 4.21% from its last close, at €3.48, in an unfavorable environment for healthcare stocks listed in Paris. Sanofi is down 2.22% in the session, while UCB falls by 0.23%. The CAC 40 itself is in negative territory, at 7,924.16 points (-0.48% in session), as is the SBF 120 (-0.48%). Despite this decline, the stock maintains an upward trajectory over longer horizons: it has risen by nearly 16% over three months and shows a gain of more than 176% over one year. The absence of a specific catalyst—neither earnings releases nor identified clinical news today—suggests that the movement is more a reflection of the general market dynamics than an event specific to the company.
Technical Analysis Insights
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical analysis perspective, the price of DBV Technologies, at €3.48, is below its 20-day (€3.59) and 50-day (€3.71) moving averages, indicating a short-term waning of bullish momentum. The stock is trading in the lower part of its Bollinger Bands, at 37% of the range between the lower bound (€3.18) and the upper bound (€3.99), which reflects a relatively low positioning without indicating an oversold situation. The RSI, at 52, remains in a neutral zone, showing neither excessive buying nor marked selling pressure. The nearest support threshold is at €3.37, a level to watch if the decline continues. It is worth noting that the monthly volatility of the stock remains high, at 22.35%, a characteristic typical of biotechnological stocks of this market capitalization.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
